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ABSTRACT
Background: Radiation therapy is the most prescribed treatment for many
oncologic indications. One of its common side effects is mucositis with hallmark
apoptosis in the intestinal crypt and diarrhea.
Objective: We investigated the potential beneficial effects of etanercept and
cyclosporin treatment during radiation exposure. The effects of these drugs on intestinal
apoptosis, long-term weight loss, diarrhea severity, and survival were examined.
Methods: For acute observation studies, animals pretreated with phosphate
buffer saline (PBS) vehicle, either etanercept, or cyclosporin were challenged with
either 1 Gy or 13 Gy irradiation and sacrificed 6 hours later. The animals’ small
intestines were then harvested for histologic analysis. For chronic survival studies,
14.5 Gy irradiation was applied. Etanercept or cyclosporin treatments were given 15
minutes before the irradiation, followed by daily administration.
Results: At 6 hours postirradiation the maximum apoptotic index observed in the
mall intestine was 25% for both 1 Gy and 13 Gy irradiation. Etanercept and
yclosporin pretreatment had no effect on the irradiation-induced apoptosis. During
hronic observation, the rate of weight loss was similar in all test groups. At 7 days
ostirradiation, the weight loss in phosphate buffered saline-treated control, etanercept,
nd cyclosporin groups reached a maximum at 19%, 24%, and 31.8%, respectively. The
eight lost in the cyclosporin group was significantly higher than in the control group.
either treatment reduced the severity of diarrhea, but cyclosporin increased the survival
ate. Sixty percent of cyclosporin-treated animals survived compared with 27% in the
BS-treated control group and 47% in the etanercept-treated group. Serum tumor
ecrosis factor- levels, a biomarker for both etanercept’s mechanism of action and
treatment efficacy, was inhibited by etanercept throughout the study, but cyclosporin only
showed an inhibitory effect at 48 hours postirradiation.
Conclusions:Our study demonstrates that cyclosporin increases the survival rate
of irradiated animals without affecting parameters such as intestinal histology, weight
loss, and diarrhea severity. (Curr Ther Res Clin Exp. 2012;73:150–164) © 2012 Elsevier
HS Journals, Inc. All rights reserved.
Accepted for publication June 27, 2012. http://dx.doi.org/10.1016/j.curtheres.2012.06.002
© 2012 Elsevier HS Journals, Inc. All rights reserved. 0011-393X/$ - see front matter
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INTRODUCTION
Radiation therapy (XRT) is a common treatment for many types of malignant cancers
that targets rapidly dividing tumor cells. The ionizing radiation can damage the
DNA of cancerous cells directly or, through the formation of free radicals, cause them
to die or proliferate at a slow rate. However, XRT also affects rapidly dividing normal
cells. Free radicals can cause c-Jun N-terminal kinase signaling and nuclear factor
kappa B (NF-kB) activation,1 leading to proinflammatory events. Epithelial cells are
of the more rapidly dividing cell populations in the intestines. They can be injured
r killed during the course of XRT. The ionizing radiation also impairs the normal
epair process, leaving the mucosa vulnerable to further injury and ulcer development.
o compound the pathology, patients undergoing chemotherapy often have neutro-
enia, making them vulnerable to secondary infection and even sepsis.2 The severity
of mucositis in many incidents is serious enough to limit the oncology treatment
options for patients.3
The pathophysiology of mucositis can be divided into 5 stages.2 According to this
lassification, epithelial DNA damage due to free radical production occurs during
he radiation exposure in the initiation phase. This initial damage is followed by a
essage generation phase. This leads to a signaling and amplification phase, followed
y ulceration, and a healing phase. NF-kB, cyclooxygenase-2, and proinflammatory
ytokines such as interleukin 1b, interleukin 6, and tumor necrosis factor-alpha
TNF-) have been linked to the pathogenesis of this condition.2,4,5 TNF- is
articularly well studied, and its increased production after irradiation is well doc-
mented.6,7 It can activate NF-kB and cause the release of other proinflammatory
ytokines, thus amplifying the signal.8,9 Due to this, the damaging effects of TNF-
release extend beyond the initial assault. Besides its proinflammatory effects, TNF-
is also an apoptotic cytokine. The role of TNF- in irradiation-induced toxicity has
been demonstrated in both tumor necrosis factor receptor 1 (TNFR1) knock-out mice
and wild-type mice treated with antisense against TNFR1.10 The targeting of the
TNF- signaling cascade led to attenuation of downstream apoptosis. This makes
TNF- an attractive target for mediating ionization-induced mucositis, and warrants
the rationale to study etanercept in irradiation-induced mucositis.
Cyclosporin A (CsA) is an 11 amino acid long fungal derived peptide.11 It is an
mmunosuppressive drug with low myelotoxicity. Its effects were originally thought
o affect mostly T and B lymphocytes,12–14 but they have been found to extend to
acrophages as well. CsA decreases human macrophage interleukin-6 synthesis at the
ost-transcriptional level15 and can decrease reactive oxygen species production in
murine macrophages stimulated by phorbol 12-myristate 13-acetate.16 Other mac-
ophage functions, including antigen presentation,17–19 migration,11,20 and prosta-
glandin E production21 can also be down regulated by CsA. Because macrophages are
a major source of TNF- production caused by irradiation, targeting macrophage
function holds the potential to modulate the pathogenesis of irradiation-induced
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Current Therapeutic Researchmucositis. Therefore, we examined the possibility of using cyclosporin and etanercept,
an antibody against TNF-, to modulate irradiation induced mucositis.
METHODS
Animals and Husbandry
Male C57B/6 mice aged 10 to 12 weeks were used in all studies. All procedures
ere certified according to the UK Animals (Scientific Procedures) Act of 1986. The
nimals were purchased from Harlan UK (Oxfordshire, United Kingdom) and
llowed to acclimatize for 2 weeks before use. Both feed (Rat and Mouse
xpanded diet, B & K, Hull, United Kingdom) and water (from drinking bottles)
ere available ad libitum. Animal health was monitored daily and cages were
leaned at regular intervals. All animals were held in individually ventilated cages
n a specific pathogen free barrier unit. The room was maintained at 21°C
2°C), 55% (10%) relative humidity, and 12-hour day-night cycles. The
nimals were identified by numbered cages and ear punches. Mice were random-
zed into groups of 8 for respective treatments.
Experimental Procedures, Clinical Scoring, and
Sample Collection
Etanercept (lot No. 34648, Wyeth, Sandwich, United Kingdom) and cyclosporin
lot No. 1361825, Fluka) were dissolved in phosphate-buffered saline, and adminis-
ered once by intraperitoneal injection followed by an immediate administration of 1
y or 13 Gy irradiation. Irradiation was performed using a Pantak HF320 x-ray
et (Agfa NDT Ltd, Reading, United Kingdom) operating at 300 kV, 10 mA.
he x-ray tube was fitted with additional filtration to give a radiation quality of
.3 mm Cu half-value layer. Mice were restrained in a jig, positioned at a distance
f 700 mm from the focus of the x-ray tube. Irradiation was delivered at a dose
ate of 75.5 cGy/minute. For the acute study, the animals were sacrificed 6 hours
ollowing the administration of the irradiation. At the time of euthanasia,
amples of the upper ileum and mid-colon were harvested and frozen, with
djacent intestinal samples fixed in formalin. The formalin-fixed samples were
rocessed to generate hematoxylin and eosin stained slides.
For the chronic study, all mice were exposed to 14.5 Gy irradiation, and dosed
aily until Day 10 with either drugs or phosphate buffered saline. Their weight and
igns of diarrhea were noted daily. During the times of peak diarrhea incidence
Days 5–10) mice were inspected twice daily for signs of diarrhea. Scores were
ecorded as 0, 1, 2, or 3 where 0 is normal stool consistency, 1 is loose stools, 2
s overt diarrhea with perianal soilage, and 3 is severe/bloody diarrhea with
ubstantial tail soilage. The daily scores were then summed to give a cumulative
core over the course of the study.
Intestinal Histologic Analysis
Mice were sacrificed by cervical dislocation. Samples of the small (ileum) and large
mid-colon) intestine were removed and fixed in Carnoy’s solution. This analytical
ethod for quantifying the number of apoptotic cells, and identifying their location
152
D. Tung et al.in mucositis models had previously been described by Letari et al22 and Tung et al.23
Briefly, the fixed small intestines were specially positioned before paraffin embedding
to obtain the ideal orientation of the crypts (Figure 1). From each mouse a series of
intestine segments, approximately 1-cm long, were placed within a loop of surgical
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Figure 1. (A) Cartoon illustrating cell positional frequency plots. Cell position 1 represents
the cells located at the base of the crypt. The positional number increases in an
ascending order away from the base. 50 crypt lengths were analyzed for each
mouse and the frequency of apoptotic cells at each cell position was plotted. (B)
Micrograph of intestinal crypt showing apoptotic cells (400 magnification).
The sections were prepared as outlined in the Method section, and stained with
hematoxylin and eosin stain. Apoptotic cells take on a rounded appearance
(white arrows), and are frequently found near the base of the crypt. (C) Mitotic
cells are often rare or difficult to capture due to the short duration of this portion
of the cell cycle. This micrograph was taken at 630 magnification to show the
detail of a mitotic cell (yellow arrow).micropore tape, and the tape tightened to immobilize the lengths. This allowed the
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Current Therapeutic Researchalignment of many pieces of fixed intestine alongside each other, so that every section
contained 10 to 12 well-orientated cross sections.
Paraffin blocks were sectioned to generate 2 nonserial sections per slide. The slides were
hematoxylin and eosin stained and the apoptotic indices analyzed for each cell position in
the crypt. Fifty half crypts per mouse were scored on a cell positional basis, generating 400
frequency scores per group of 8 animals, from which the means were generated.
Longitudinal Serum TNF- Analysis
For longitudinal TNF–-level analysis, groups of irradiated mice were euthanized
at 0.5, 2, 4, 6, and 8 days postirradiation. At the time of euthanasia, plasma was
collected and frozen in aliquots. Antibody coupled beads (10 concentration) were
quickly spun and then gently re-suspended with a pipette and diluted to working
concentration (1) using assay buffer. Beads were then added to prewetted filter plates.
After binding, the plates were washed and diluted standards, samples, and controls were
added. Samples were then incubated on a shaker at room temperature for 30 minutes.
After washing, the bound antigen was detected by incubating with the detection antibody
and further incubated on a shaker for 30 minutes at room temperature. After an additional
plate washing step, label was detected using Streptavidin-PE (BioSupply, Oxford, United
Kingdom). Plates were incubated, washed, and then read using the Biorad Bioplex system
(BioRad, Hertfordshire, United Kingdom).
Data Analysis
The statistical analysis of apoptosis indices was performed using the WinCrypts
ersion 2 (Released in 2002) software (C2SG, Cambridge, United Kingdom) that utilized
n extension of the median test. At each cell position, the common median for all animals
as calculated by combining the groups. The individual values for each animal were
lassified as being below or above the median. These values were then cast on a 2  2
ontingency table for each position and a 2 test was applied. For survival analysis, the
Cox proportional hazard regression model was used. The proportional odds model was
used to analyze the cumulative diarrhea score. P  0.05 was considered significant in all
nalyses. The group size was determined using power analysis according to the Point-
iserial correlation model with a desired power of 0.95. The effect size || was calculated
to be 0.707, based on a coefficient of determination value of 0.5.
RESULTS
Effect of Etanercept and Cyclosporin Treatment on the
Apoptotic Index
The effects of cyclosporin and etanercept treatment on intestinal crypt cell apop-
osis at 6 hours following 1 Gy and 13 Gy irradiation were examined. The data were
ummarized as cell positional plots (Figure 2). In normal tissue, the baseline level of
pontaneous apoptosis was low, as reflected in low apoptotic index throughout the
rypt. Irradiation induced significant apoptosis in the crypt epithelial cells, especially
t cell positions 1 through 13. Cells in the vicinity of positions 3 through 7 were
articularly sensitive. This region was rich with radiosensitive stem cells that were
nable to repair DNA damage (Figure 1B). These apoptotic cells generally take on
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D. Tung et al.a round appearance. The maximum apoptotic index observed was 25% for both
levels of irradiation. For 1 Gy irradiation, neither etanercept nor cyclosporin signif-
icantly affected the number of apoptotic cells (Figure 2A).
The induction of apoptosis by 13 Gy irradiation followed a similar pattern as the
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Figure 2. Cell positional frequency plots of apoptotic index after exposure to irradiation.
The base line apoptotic index of the naïve animals (Œ) is also shown. (A) The
frequency of apoptosis in all treatment groups was significantly elevated over
naïve animals in positions 1–14 (P < 0.05). Etanercept () and cyclosporin (50
and 100 mg/kg) (‘, ) treatment had no effect on the frequency of crypt cell
apoptosis after 1 Gy irradiation. Etanercept (25 mg/kg) and cyclosporin were
administered just before the irradiation. Apoptosis at cell positions 15–21 was
generally not observed. (B) 13 Gy irradiation significantly increased the number
of apoptotic cells over naïve animals in positions 1–11 for the phosphate
buffered PBS-treated group, positions 1–12 for the 25 mg/kg etanercept group,
and positions 1–13 for the cyclosporin groups. Etanercept (25 mg/kg) () and
cyclosporin (50 and 100 mg/kg) (‘, ) given before the irradiation had no
effect on the apoptotic index. The pattern of apoptosis at the 13-Gy irradiation
level was similar to the 1-Gy level. There was no significant difference in the
frequency of crypt cell apoptosis in the PBS-treated animals caused by 1 Gy and
13 Gy irradiation.1-Gy dose. However, a slightly wider crypt cell population of clonogenic cells was
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Current Therapeutic Researchkilled. At this high level of irradiation, the first wave of the induced apoptosis occurs
within 6 hours, followed by mitotic collapse and a second wave of cell death after
approximately 24 hours (data not shown). Irradiation at a dose of 13 Gy induced a
statistically significant increase in apoptosis over cell positions 1 through 10. At 6 hours
postirradiation, 25 mg/kg etanercept increased the level of apoptosis. However, this
increase was not statistically significant. Both doses of cyclosporin increased the level of
the apoptotic index. This increase was significant at cell positions 5 through 13 for the
50-mg/kg dose, and cell positions 5 through 8 and 10 for the 100-mg/kg dose.
Effects of Etanercept and Cyclosporin Treatment on
Weight Loss, Diarrhea Score, and Survival
Immediately after the animals received their respective treatments, they were
xposed to 14.5 Gy irradiation and observed for 14 days. The animals received further
reatment on a daily basis. Weight loss was observed in all treatment groups
ollowing exposure to irradiation (Figure 3). Seven days postirradiation, the weight
oss in all treatment groups began to plateau, reaching a maximum of 19%, 24%, and
1.8% for phosphate buffered saline-treated control, etanercept, and cyclosporin
roups, respectively. There was no difference in the rate of weight loss in the
reatment groups. However, the percent weight loss in the cyclosporin-treated
40
35
30
25
20
15
10
5
0
0 2 4 6 8
Days
W
ei
gh
t 
lo
ss
 (%
)
10 12 14
Vehicle
25 mg/kg etanercept
100 mg/kg cyclosporin
∗ ∗
∗
∗
∗
∗
∗
∗ ∗ ∗
∗ ∗
∗ ∗
Figure 3. Effects of etanercept () and cyclosporin (‘) treatment on weight loss after
14.5-Gy partial body irradiation. The animals received daily dosing of either
treatment. The percent weight loss in the cyclosporin-treated animals were
significantly higher than the PBS-treated animals throughout the study. There
was no statistical difference in the weight loss between the PBS-treated group
and etanercept-treated animals. The weight loss in all groups reached a plateau
after 7 days. *P < 0.05.nimals was significantly higher than that of the phosphate buffered saline-treated
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PBS group.
Daily observations were made to quantify the number of animals experiencing
diarrhea after exposure to irradiation (Figure 4). The onset of diarrhea usually took
place at the end of Day 4 of the model. Treatment with neither drug reduced the level
of diarrhea. Five days following irradiation, 67% of PBS-treated mice had demon-
strable diarrhea compared with 75% of the cyclosporine group and 53% of the
etanercept group. By the end of the study, 67% of PBS-treated mice experienced
diarrhea, compared with 91% in the cyclosporine group and 69% in the etanercept
group. There was no significant treatment effect on the diarrhea scores from both
drugs compared with the PBS-treated animals.
The animals in all treatment groups began to die at 6 days postirradiation. At 10
days postirradiation, the decline in the number of surviving animals reached a
plateau. The rate of death was slower in the cyclosporin and etanercept groups. The
final number of surviving animals in both drug treatment groups was also higher:
27% in the PBS-treated group survived compared with 47% and 60% in the
etanercept- and cyclosporine-treated groups, respectively. Despite the lack of effect on
weight loss and diarrhea score, cyclosporin treatment significantly increased the
survival rate of the mice (Figure 5). Even though etanercept treatment increased the
number of surviving animals at the end of the study, this increase was not signifi-
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Figure 4. Effects of cyclosporin and etanercept treatment on the diarrhea severity of
the 14.5-Gy irradiated animals. The cumulative diarrhea score increased
exponentially 7 days following irradiation. The severity of diarrhea in the
PBS-treated and etanercept-treated animals plateau after 15 days. Etaner-
cept had no effect on diarrhea severity. Cyclosporin treatment slightly ag-
gravated the diarrhea in the irradiated animals.cantly different than in the PBS-treated group.
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TNF- Production
Designated groups of mice were sacrificed at specific time points after irradiation.
lasma levels of TNF- were quantified (Figure 6). Circulating TNF- levels were
dramatically upregulated from the baseline level of 137.6 pg/mL to 881.3 pg/mL
within 12 hours of irradiation, and remained elevated throughout the 8-day obser-
vation period. Etanercept treatment significantly decreased TNF- level to 606.5
pg/mL by Day 2, and continued to suppress its level until the end of the study period.
Cyclosporin treatment briefly suppressed TNF- level to 499.5 pg/mL on Day 2. But
there was no significant inhibitory effect during the rest of the experiment.
DISCUSSION
Mucositis is a common side effect of radiation therapy that affects a large proportion
of oncology patients. The initial toxic symptoms of nausea and vomiting are usually
followed by diarrhea. It occurs in approximately 40% of patients receiving standard
dose chemotherapy and 100% of patients receiving high-dose chemotherapy and stem
cell or bone marrow transplantation.24,25 Many of these symptoms are thought to be
ssociated with epithelial damage, which is preceded by microvasculature damage.26
Ionizing radiation 10 Gy is lethal for mammals.27 Even a lower radiation
exposure in the order of 1 to 2 Gy is known to activate the extracellular signal
regulated kinases (ERK) pathway through radiation-induced free radicals28 and
proinflammatory cytokines.7,29,30 This results in epithelial changes that are associated
ith inflammatory events such as macrophage activation.31–33 During long-term
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Figure 5. Effects of cyclosporin and etanercept treatment on the survival of 14.5-Gy
irradiated animals. Fifteen animals were assigned to each treatment group at
the beginning of the study. Death of the animals was first observed at Day 5
postirradiation. Daily treatment with cyclosporin significantly increased the
survival rate of the animals at the end of the study. The number of surviving
animals in the etanercept-treated group was also higher than the PBS-treated
animals. But this difference was not statistically significant.rradiation exposure, an increase in crypt and villus length is also observed.34 In our
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of lethal and sublethal doses of irradiation.
There is strong rationale for examining the potential therapeutic role of etanercept
and cyclosporin in radiation protection. Proinflammatory cytokines, especially
TNF-, have been implicated in the pathogenesis of radiation-induced mucositis.35
In mouse oral mucosa, irradiation-induced upregulation of TNF- and cyclooxygen-
ase-236 antisense treatment against TNFR1 has shown radioprotective effects.37
Macrophages are 1 of the key cell types that mediate inflammatory responses.
Cyclosporin has been shown to downregulate proinflammatory cytokine production
by both human and rodent macrophages.38–40 Thus, the potential therapeutic effects
of etanercept and cyclosporin were studied in our experiments.
We demonstrated that 1 Gy and 13 Gy irradiation led to apoptosis in the intestinal
crypt. The apoptotic index increased toward the apical surface of the crypt. Interest-
ingly, increasing the level of irradiation to 13 Gy did not increase apoptosis. It is
possible that the level of apoptosis at 6 hours postradiation had reached maximum
with the 1 Gy radiation dose, and the higher level of irradiation could have a stronger
effect on the apoptosis at a later time. But the time course of apoptosis onset was
beyond the scope of this set of studies. Both cyclosporin and etanercept did not affect
the level of apoptosis. It is possible that the apoptosis process observed at 6 hours
postirradiation might not be TNF- and calcineurin dependent.
In pilot studies, terminal deoxynucleotidyl transferase dUTP nick end labeling
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Figure 6. Effects of etanercept and cyclosporin treatment on circulating TNF- level.
Irradiation upregulated serum tumor necrosis factor-alpha (TNF-) level from
baseline within 12 hours. This high level was maintained throughout the exper-
imental period. Etanercept treatment consistently downregulated this increase.
Cyclosporin only significantly downregulated the circulating TNF- level at the
48 hours time point. *P < 0.05.TUNEL) staining was explored as a potential end point. Unfortunately, it proved to
159
c
p
i
l
e
Current Therapeutic Researchbe an unreliable marker for this particular model. During the optimization process for
the TUNEL protocol, hematoxylin and eosin staining and morphologic analysis were
used as the benchmark. There were random incidents of false positives and negatives
that did not correlate with the histologic observations. After much optimization and
consideration, histologic analysis based on hematoxylin and eosin staining and mor-
phology was chosen as the prefered method to quantify apoptotic cells. This method
is more labor intensive; however, it is also more reproducible and reliable, as
previously demonstrated in similar models.22,23 The method employed in our study
enabled us to quantify the amount of apoptotic cells, and also graphically record their
location.
The long-term effects of etanercept and cyclosporin on various clinical parameters
were studied in animals exposed to 14.5 Gy irradiation. Cyclosporin treatment
significantly increased the survival of these animals. But the weight loss and cumu-
lative diarrhea score were not affected by either treatment. This was a surprising
finding because both factors are thought to reflect general health and thus affect
survival rate.41–43 However, there is also evidence that weight loss and survival rate
might not be closely linked. Using an adenosine derivative, Hou et al44 found a
disconnect between prevention of weight loss and survival rate in mice exposed to 12
Gy irradiation. This is in line with our observation. The cumulative diarrhea score
began to plateau after 13 days, and the weight loss of the animals reached a refractory
point after 8 days. This suggests that the radiation-induced damage was self-limiting
in this model. Perhaps multiple exposures to irradiation during the course of the
study would cause the weight loss and diarrhea to progress. But most importantly,
these data demonstrate that weight loss and diarrhea alone are not accurate predictors
of survival rate of animals. Other observable symptoms that sometimes accompanied
weight loss and diarrhea were lowering of body temperature and inactivity. However,
these end points were not easily quantifiable. The animals that sustained 20%
weight loss with a lower body temperature and lack of mobility/grooming were
immediately euthanized per Institutional Animals Care and Use Committee guide-
lines. Animals that lost 20% of original body weight but were still active and warm
were kept under a special 12-hour observation. If an animal lost further weight at the
end of the observation period it was then euthanized, and weight was recorded at that
point. These preeuthanasia weights were usually lower than the 20% guideline, and
thus, lowered the overall weight of the group. The animals that exhibited these
additional side effects were euthanized.
Radiation therapy and chemotherapy can cause significant release of proin-
flammatory cytokines from various tissues.29,30,45 TNF-, in particular, has been
onsidered a main driving cytokine in many inflammatory processes.35 But its
ivotal role in mucositis pathology has been questioned. In a murine irradiation-
nduced oral mucositis model, Haagen et al36 found no affect of infliximab on the
evel of mucosal ulceration. Those authors concluded that TNF- did not play a
major role in the incidence and time course of irradiation-induced epithelial
changes. In our study, the circulating level of TNF- was used as a marker of
fficacy, as well as a biomarker for the mechanism of action for etanercept.
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D. Tung et al.Etanercept treatment significantly downregulated circulating TNF- levels, and
ncreased the survival of the animals. However, it did not affect the diarrhea score,
eight loss, or the apoptotic index. There is a clear disconnect between these
arameters and the long-term survival of the animals. This disconnect was also
een in animals receiving cyclosporin. It appears that local events such as the level
f epithelial apoptosis and mitosis can affect subsequent parameters such as
eight loss and diarrhea severity, but they are not predictive of the long-term
urvival of the animals.
In our study, we quantified irradiation-induced local changes in the intestinal
pithelium, which led to subsequent weight loss and diarrhea. We further
emonstrated the disconnect between these parameters and the survival of the
nimals. Even though some investigators have reported upregulation of TNF-
and also activation of macrophages postirradiation, treatment with etanercept and
cyclosporin did not affect many parameters. It is possible that the increase in
TNF- expression is incidental, and other pathways can compensate for the
TNF- inhibition. The interaction of different cytokines and inflammatory cell
types is complex, and it is likely that targeting TNF- alone is not enough to
affect these pathologies. The determination of local TNF- level is beyond the
scope of this study because it will require a large number of animals to be
sacrificed over a period of time. Given the fact that both etanercept and cyclo-
sporin were dosed at the highest tolerated dose in our model, there is little
therapeutic window to further optimize the local effects. Further investigation is
required to establish the relationship between various proinflammatory cytokines
and these disease parameters.
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